The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity

Journal of Lipid Research

Volumn 48, Issue 7, 2007, Pages 1637-1646

  Gaidukov, Leonid ^a   Tawfik, Dan S ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Atherosclerosis; Blood tests; Enzyme stability; High density lipoprotein bound enzymes; Lactones; Lipoproteins; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CHROMOGENIC SUBSTRATE; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; LACTONE; LIPOLACTONASE; PHOSPHOTRIESTERASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; CATALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME BLOOD LEVEL; ENZYME INACTIVATION; ENZYME STABILITY; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL;

4-BUTYROLACTONE; ARYLDIALKYLPHOSPHATASE; ENZYME TESTS; HUMANS; LIPOPROTEINS, HDL; PHOSPHORIC ACID ESTERS; UMBELLIFERONES;

EID: 34548178347     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D600045-JLR200     Document Type: Article

References (51)

1. Lusis, A. J. 2000. Atherosclerosis. Nature. 407: 233-241.
2. Draganov, D. I., and B. N. La Du. 2004. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch. Pharmacol. 369: 78-88.
3. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
4. Aviram, M., S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlop, and B. La Du. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18: 1617-1624.
5. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135.
6. Rosenblat, M., J. Vaya, D. Shih, and M. Aviram. 2005. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis. 179: 69-77.
7. Rozenberg, O., D. M. Shih, and M. Aviram. 2003. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 23: 461-467.
8. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
9. Rozenberg, O., M. Rosenblat, R. Coleman, D. M. Shih, and M. Aviram. 2003. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34: 774-784.
10. Ayub, A., M. I. Mackness, S. Arrol, B. Mackness, J. Patel, and P. N. Durrington. 1999. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19: 330-335.
11. Mackness, B., P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 107: 2775-2779.
12. Navab, M., S. Hama-Levy, B. J. Van Lenten, G. C. Fonarow, C. J. Cardinez, L. W. Castellani, M. L. Brennan, A. J. Lusis, A. M. Fogelman, and B. N. La Du. 1997. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99: 2005-2019.
13. Khersonsky, O., and D. S. Tawfik. 2005. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 44: 6371-6382.
14. Draganov, D. I., J. F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B. N. La Du. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46: 1239-1247.
15. Khersonsky, O., and D. S. Tawfik. 2006. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem. 281: 7649-7656.
16. Rosenblat, M., L. Gaidukov, O. Khersonsky, J. Vaya, R. Oren, D. S. Tawfik, and M. Aviram. 2006. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281: 7657-7665.
17. Blatter, M. C., R. W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
18. Harel, M., A. Aharoni, L. Gaidukov, B. Brumshtein, O. Khersonsky, R. Meged, H. Dvir, R. B. Ravelli, A. McCarthy, L. Toker, et al. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11: 412-419.
19. Gaidukov, L., and D. S. Tawfik. 2005. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with apoA-I. Biochemistry. 44: 11843-11854.
20. Smolen, A., H. W. Eckerson, K. N. Gan, N. Hailat, and B. N. La Du. 1991. Characteristics of the genetically determined allozymic forms of human serumparaoxonase/arylesterase. Drug Metab. Dispos. 19: 107-112.
21. Humbert, R., D. A. Adler, C. M. Disteche, C. Hassett, C. J. Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
22. Davies, H. G., R. J. Richter, M. Keifer, C. A. Broomfield, J. Sowalla, and C. E. Furlong. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14: 334-336.
23. Leviev, I., S. Deakin, and R. W. James. 2001. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J. Lipid Res. 42: 528-535.
24. Leviev, I., F. Negro, and R. W. James. 1997. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 17: 2935-2939.
25. Leviev, I., and R. W. James. 2000. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521.
26. Brophy, V. H., M. D. Hastings, J. B. Clendenning, R. J. Richter, G. P. Jarvik, and C. E. Furlong. 2001. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 11: 77-84.
27. Gaidukov, L., M. Rosenblat, M. Aviram, and D. S. Tawfik. 2006. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J. Lipid Res. 47: 2492-2502.
28. Mackness, M., and B. Mackness. 2004. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic. Biol. Med. 37: 1317-1323.
29. Jarvik, G. P., T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. 2003. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 1465-1471.
30. Mueller, R. F., S. Hornung, C. E. Furlong, J. Anderson, E. R. Giblett, and A. G. Motulsky. 1983. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am. J. Hum. Genet. 35: 393-408.
31. Ortigoza-Ferado, J., R. J. Richter, S. K. Hornung, A. G. Motulsky, and C. E. Furlong. 1984. Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am. J. Hum. Genet. 36: 295-305.
32. Eckerson, H. W., J. Romson, C. Wyte, and B. N. La Du. 1983. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am. J. Hum. Genet. 35: 214-227.
33. Eckerson, H. W., C. M. Wyte, and B. N. La Du. 1983. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35: 1126-1138.
34. La Du, B. N., J. I. Piko, H. W. Eckerson, M. Vincent-Viry, and G. Siest. 1986. An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism. Ann. Biol. Clin. (Paris). 44: 369-372.
35. Blatter Garin, M. C., C. Abbott, S. Messmer, M. Mackness, P. Durrington, D. Pometta, and R. W. James. 1994. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem. J. 304: 549-554.
36. Rosenblat, M., R. Karry, and M. Aviram. 2006. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis. 187: 74-81.
37. Khersonsky, O., and D. S. Tawfik. 2006. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. ChemBioChem. 7: 49-53.
38. Billecke, S., D. Draganov, R. Counsell, P. Stetson, C. Watson, C. Hsu, and B. N. La Du. 2000. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28: 1335-1342.
39. Aharoni, A., L. Gaidukov, O. Khersonsky, S. McQ. Gould, C. Roodveldt, and D. S. Tawfik. 2005. The 'evolvability' of promiscuous protein functions. Nat. Genet. 37: 73-76.
40. Blatter Garin, M. C., X. Moren, and R. W. James. 2006. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J. Lipid Res. 47: 515-520.
41. van Himbergen, T. M., M. Roest, J. de Graaf, E. H. Jansen, H. Hattori, J. J. Kastelein, H. A. Voorbij, A. F. Stalenhoef, and L. J. van Tits. 2005. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. Lipid Res. 46: 445-451.
42. Martinelli, N., D. Girelli, O. Olivieri, U. Cavallari, M. Biscuola, E. Trabetti, S. Friso, F. Pizzolo, I. Tenuti, C. Bozzini, et al. 2005. Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease. Clin. Exp. Med. 5: 20-30.
43. Ruiz, J., H. Blanche, R. W. James, M. C. Garin, C. Vaisse, G. Charpentier, N. Cohen, A. Morabia, P. Passa, and P. Froguel. 1995. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346: 869-872.
44. Serrato, M., and A. J. Marian. 1995. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96: 3005-3008.
45. Antikainen, M., S. Murtomaki, M. Syvanne, R. Pahlman, E. Tahvanainen, M. Jauhiainen, M. H. Frick, and C. Ehnholm. 1996. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98: 883-885.
46. Herrmann, S. M., H. Blanc, O. Poirier, D. Arveiler, G. Luc, A. Evans, P. Marques-Vidal, J. M. Bard, and F. Cambien. 1996. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 126: 299-303.
47. Wheeler, J. G., B. D. Keavney, H. Watkins, R. Collins, and J. Danesh. 2004. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 363: 689-695.
48. Ferre, N., M. Tous, A. Paul, A. Zamora, J. J. Vendrell, A. Bardaji, J. Camps, C. Richart, and J. Joven. 2002. Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin. Biochem. 35: 197-203.
49. Jarvik, G. P., L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 20: 2441-2447.
50. Rozek, L. S., T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. 2005. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J. Lipid Res. 46: 1888-1895.
51. Vasan, R. S. 2006. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 113: 2335-2362.